Subscribe to NRx Newsletter
2nd quarter financial results3PLAccelerated RecoveryACTIV-3ACTIV-3bActive3bAcute Respiratory Distress SyndromeAcute Respiratory FailureAdaptive Platform Trial DesignAnnual Global Investment ConferenceAnthony S Fauci MDARDSAviptadilAvitpadilBARDABig Rock PartnersbiobuzzBioConnect Virtual ConferenceBiotechBipolar DepressionBNP ParibasBoosterBreakthrough Therapy DesignationBRilifeBRILife®BTDCAHCardinal HealthCEOCEO updateCFOCH HealthChaim HurvitzCheddar NewsChief Executive OfficerChief Financial OfficerClinical Trialsclinical updateClosing BellCOID-19Commercial ForumlationCompany PresentationCompassionate CareconferenceCovidCovid-19COVID-19 SurvivalCOVID-AIVCovid19Critical COVID-19CromosCytokine IL-6Cytokine StormCytokinesDal BoscoDaniel JavittData Safety Monitoring BoardDeltaDelta VariantDenk PharmadepressionDirectorDisease preventionDisease prevention & Control SummitDr YoDr. Sami SaidDr. Shmuel YitzhakiDry-powder InhalerDSMBEAPEkaterine TikaradzeEmegency Use AuthorizationEmergency UseEmergency Use Authorizationerectile dysfunctionEUAEuropean QPExpanded AccessFast TrackFDAFDA EmeFDA Emergency Use AuthorizationFDA Module 3Federal Right to Try ActFinancial ResultsFox BusinessGeorgiaGeorgia Society of PhysiciansGeorgian Ministry of HealthGILDGileadGovernment of LuxembourgH.C. WainwrightH.C. Wainwright & Co.HC WainwrightHC Wainwright Annual Global Investment ConferenceHC Wainwright Global Investment ConferenceHigh Flow NasalHoustonHouston MethodistHouston Methodist JC Walkter Jr Transplant CenterI-Spyi24 NewsICUIIBRIL-6 CytokineInhaled AviptadilIQVIQVIAIra StrassbergiSpyIsraelIsrael Institute of Biological ResearchIV ZYESAMI®J. Georges YoussefJ&JJihad Georges YoussefJihad Georges Youssef MDJihad Geroges YoussefJonathan JavittJournal of Infectious Diseases and TreatmentlawsuitLuxembourgLuxembourg Ministry of the EconomyMannkindMDMental HealthMNKDMolnupiravirNanoPassNASDAQNation of GeorgiaNational Institutes of HealthNDA ZyesamiNeedhamNehpron PharmaceuticalsNephronNephron PharmaceuticalsNeuropsychiatryNIAIDNIHNRXNRx BriLife COVID VaccineNRx Business UpdateNRx EarningsNRx PharmaNRx PharmaceuticalsNRX-100NRX-100/101NRX-101NRX101NRXPOmicronOrphan Drug DesignationPandemicPeptidesPharmacovigilancePhase 2presentationPrivate PlacementProf Jonathan JavittProf Jonathan Javitt MD MPHPsychedelicsPsychiatric CarePsychiatryPTSDQ1 EarningsQ2 EarningsQ3 Finaincial ResultsQP AuditorQP DeclarationQuantum Leap HealthcareRelief TherapeuticsRemdesivirRespiratory Distress RatioRespiratory FailureRichard G Lugar Center for Public HealthRichard Luger CenterRIght to TryRightToTryRLF-100RLF-100_002Robert BesthofRTTSami SaidSar-CoV-2Sars-CoV-2serotoninSeth Van VoorheessettlementSever COVID-19Stephen WillardSuicidal DepressionSuicidalityTechnosphereTESICOTreasurerUCIUkraineUS Food and Drug AdministrationUSFDAVaccineVaccine TrialVaccine TrialsVasoactive Intestinal PeptideVekluryVIPVirologywebcastZYESAMIZYESAMI®ZYESAMI® (aviptadil)ZYESAMI™ZYESAMI™ INDZysamiZYSAMI®ZYSAMI® (aviptadil)